8-K: Evoke Pharma Secures Key Patent for GIMOTI, Extending Market Exclusivity to 2036

Evoke Pharma, Inc. announced it has received a Notice of Allowance for a U.S. patent application covering GIMOTI, extending its market exclusivity for the gastroparesis treatment until December 2036.

Summary

• Evoke Pharma received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application covering the use of GIMOTI in patients with moderate to severe symptoms of gastroparesis.
• The allowed application is a continuation of U.S. Patent No. 11,517,545, which further expands Evoke's intellectual property estate around intranasal metoclopramide.
• Upon issuance, the new patent is expected to expire in December 2036, extending market exclusivity for GIMOTI beyond other existing patents.
• Evoke intends to list this new patent in the FDA's Orange Book.
• The company has filed another U.S. continuation application to pursue additional claims directed to treatments for this patient population.

Sentiment

Score: 8

Explanation: The patent allowance significantly strengthens the company's intellectual property and extends market exclusivity for its key product, GIMOTI, which is a strong positive for future revenue and competitive positioning.

Positives

• Receipt of a Notice of Allowance for a new U.S. patent for GIMOTI, strengthening intellectual property.
• Extension of market exclusivity for GIMOTI until December 2036, providing an additional 6 years of protection beyond existing patents.
• The new patent adds meaningful value to the GIMOTI franchise by reinforcing protection around its use.
• GIMOTI is highlighted as an effective non-oral treatment, which is crucial for gastroparesis patients whose condition can compromise oral medication absorption.
• GIMOTI is the only FDA-approved, non-oral, self-administered formulation of metoclopramide.
• Metoclopramide remains the only drug currently approved in the United States to treat gastroparesis.

Risks

• Ability to obtain and maintain intellectual property protection for GIMOTI.
• The FDA ultimately updating the Orange Book listing with the new patent.
• Evoke and EVERSANA may not be able to successfully drive market demand for GIMOTI.
• Market research studies may not accurately predict acceptance by patients, healthcare providers, or payors.
• Evoke is entirely dependent on the success of GIMOTI.
• Inadequate efficacy or unexpected adverse side effects relating to GIMOTI could result in recalls or product liability claims.
• Other risks and uncertainties detailed in Evoke's prior press releases and periodic reports filed with the Securities and Exchange Commission.

Future Outlook

Evoke plans to list the newly allowed patent in the FDA's Orange Book to extend market exclusivity for GIMOTI beyond existing patents. The company also intends to pursue additional claims directed to treatments for certain patient populations by filing another U.S. continuation application. Management remains focused on maximizing GIMOTI's potential as an effective patient-friendly treatment for diabetic gastroparesis.

Management Comments

• "This new patent allowance adds meaningful value to the GIMOTI franchise by reinforcing protection around how and in whom the therapy is used." Matt D'Onofrio, CEO of Evoke Pharma.
• "Backed by extensive market research, GIMOTI continues to stand out as an effective non-oral treatment for a disease that can compromise the effectiveness of pills due to slowed gastric absorption of oral medications." Matt D'Onofrio, CEO of Evoke Pharma.
• "We remain focused on maximizing GIMOTI’s potential as an effective patient-friendly treatment for diabetic gastroparesis." Matt D'Onofrio, CEO of Evoke Pharma.

Industry Context

The announcement reinforces Evoke's position in the specialty pharmaceutical market, particularly for gastrointestinal disorders. GIMOTI's non-oral delivery method addresses a critical need for gastroparesis patients, whose condition often impairs the absorption of oral medications. This patent strengthens its competitive advantage in a niche but significant therapeutic area, where metoclopramide is the only FDA-approved drug for gastroparesis.

Comparison to Industry Standards

• GIMOTI is the only FDA-approved, non-oral, self-administered formulation of metoclopramide for acute and recurrent diabetic gastroparesis in adults.
• Metoclopramide (the active ingredient in GIMOTI) remains the only drug currently approved in the United States to treat gastroparesis, distinguishing it from other potential treatments or symptomatic relief options.
• The non-oral delivery method of GIMOTI provides a significant advantage over traditional oral medications for gastroparesis patients, whose condition can compromise oral absorption.

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to extended market exclusivity and strengthened intellectual property for GIMOTI.
• Patients: Continued availability and potential for improved treatment options for those with moderate to severe gastroparesis symptoms, especially given GIMOTI's non-oral delivery advantage.
• Healthcare Providers: Reinforced confidence in prescribing GIMOTI due to extended patent protection and its unique non-oral formulation.

Next Steps

• Issuance of the patent by the USPTO.
• Listing the new patent in the FDA's Orange Book.
• Pursuing additional claims directed to treatments for certain patient populations through another U.S. continuation application.
• Supporting Gastroparesis Awareness Month in August.

Key Dates

Recommendation

Keywords

Evoke Pharma, GIMOTI, metoclopramide, gastroparesis, patent, USPTO, FDA Orange Book, market exclusivity, pharmaceutical, gastrointestinal disorders, nasal spray, intellectual property